VEGF has been the target of diverse pre-clinical and clinical prostate cancer trials, but the therapeutic response and survival outcomes remain “a road less taken” to impair advanced disease and impact patients in clinical practice [59]. The gene discussed is VEGFA; the disease is prostate carcinoma.